&lt;p&gt;Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats&lt;/p&gt;

Dota, Atsuyoshi; Sakamoto, Asuka; Nagano, Takashi; Murakami, Tadahiro; Matsugi, Takeshi

doi:10.2147/opth.s242764

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decreased tear secretion, less innervation, delayed epithelial wound healing, and weakened cell junction was found in diabetic rats [ 130 , 131 ]. In diabetic mice in which scopolamine hydrobromide was systemically administered to induce dry eye, tear production significantly declined and displayed corneal epithelial defects [ 132 ].…”

Section: Evidence Of Changes In Ocular Surface and Immune Response In...mentioning

confidence: 99%

Immune Fingerprint in Diabetes: Ocular Surface and Retinal Inflammation

Amorim

Martins

Fernandes

2023

IJMS

View full text Add to dashboard Cite

Diabetes is a prevalent global health issue associated with significant morbidity and mortality. Diabetic retinopathy (DR) is a well-known inflammatory, neurovascular complication of diabetes and a leading cause of preventable blindness in developed countries among working-age adults. However, the ocular surface components of diabetic eyes are also at risk of damage due to uncontrolled diabetes, which is often overlooked. Inflammatory changes in the corneas of diabetic patients indicate that inflammation plays a significant role in diabetic complications, much like in DR. The eye’s immune privilege restricts immune and inflammatory responses, and the cornea and retina have a complex network of innate immune cells that maintain immune homeostasis. Nevertheless, low-grade inflammation in diabetes contributes to immune dysregulation. This article aims to provide an overview and discussion of how diabetes affects the ocular immune system’s main components, immune-competent cells, and inflammatory mediators. By understanding these effects, potential interventions and treatments may be developed to improve the ocular health of diabetic patients.

show abstract

Section: Evidence Of Changes In Ocular Surface and Immune Response In...mentioning

confidence: 99%

Immune Fingerprint in Diabetes: Ocular Surface and Retinal Inflammation

Amorim

Martins

Fernandes

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Additionally, diquafosol improved ocular surface health and mitigated corneal epithelial damage caused by superficial punctate keratopathy. An instillation of diquafosol was associated with an increase in Periodic acid-Schiff (PAS)-stained positive goblet cells in the rat dry-eye model [ 74 ] and a significant decrease in corneal fluorescein staining scores compared to controls in a diabetic rat model [ 84 ].…”

Section: P2y 2 Receptor Agonist: Diquafosolmentioning

confidence: 99%

The developmental journey of therapies targeting purine receptors: from basic science to clinical trials

Han

Suzuki-Kerr

Vlajkovic

et al. 2022

Purinergic Signalling

View full text Add to dashboard Cite

Since the discovery of ATP as an extracellular signalling molecule in 1972, purinergic signalling, mediated by extracellular purines and pyrimidines has been identified in virtually all mammalian tissues and is implicated in regulating fundamental cellular processes. In recent years, there has been an increasing focus on the pathophysiology and potential therapeutic interventions based on purinergic signalling. A vast range of compounds targeting purine receptors are in clinical development, and many more are in preclinical studies, which highlights the fast growth in this research field. As a tribute to Professor Geoffrey Burnstock’s legacy in purinergic signalling, we present here a brief review of compounds targeting purine receptors that are in different stages of clinical trials. The review highlights the 50-year journey from basic research on purinergic receptors to clinical applications of therapies targeting purine receptors.

show abstract

“…8 Diquafosol tetrasodium (DQS) topical ophthalmic solution is a dinucleotide polyphosphate which is a purinoceptor agonist; when administered to the ocular surface, it binds to P2Y 2 receptors and stimulates mucin and tear secretion. [9][10][11] It also improves the tear film composition and stability. [12][13][14] It has a corneal epithelial-repairing effect and can be used to treat ocular surface damage caused…”

Section: Introduction Background and Rationalementioning

confidence: 99%

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

Chen,

Qin,

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionEvaporative dry eye (EDE) is common and can lead to ocular pain, decreased visual quality and reduced quality of life. Intense pulsed light (IPL) and 3% diquafosol ophthalmic solution have been found to be beneficial in reducing signs and symptoms of dry eye.Methods and analysisA randomised clinical trial will be performed at He Eye Specialist Hospital in Shenyang. 360 dry eye disease patients will be equally divided randomly into the IPL group, DQS group (3% diquafosol ophthalmic solution eye-drops) and IPL+group (IPL combined with 3% diquafosol eye-drops). All groups will be followed up for 4 weeks. The primary outcome measures will be the non-invasive tear break-up time and the Ocular Surface Disease Index change from the baseline. The secondary outcome measures willincludeconjunctival and cornea staining with fluorescein and lissamine, meibomian gland function and secretion quality, tear film lipid layer score, tear meniscus height, conjunctival hyperemia (redness score) changes . Adverse events also will be monitored and documented.DiscussionThis study aimed to assess whether the combination of IPL with 3% diquafosol ophthalmic solution (study group), IPL+ (study group), is more effective than IPL (active control group) or DQS (active control group) in participants with EDE.Ethics and disseminationManagement of dry eye with IPL combined with 3% diquafosol ophthalmic solution, registered on 23 January 2023. Ethics approval number: IRB (2022) K029.01. The study’s findings will be shared regardless of the effect’s direction.Trial registration numberNCT05694026.

show abstract

<p>Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats</p>

Cited by 8 publications

References 27 publications

Immune Fingerprint in Diabetes: Ocular Surface and Retinal Inflammation

Immune Fingerprint in Diabetes: Ocular Surface and Retinal Inflammation

The developmental journey of therapies targeting purine receptors: from basic science to clinical trials

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

Contact Info

Product

Resources

About